TAPENTADOL HYDROCHLORIDE Drug Interactions
Also known as: Tapentadol Hydrochloride
TAPENTADOL HYDROCHLORIDE (brand name: Tapentadol Hydrochloride) is a Opioid Analgesics. 1 INDICATIONS AND USAGE Tapentadol tablets are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can…TAPENTADOL HYDROCHLORIDE has 17 documented drug interactions in our database, including 6 contraindicated, 11 major, 0 moderate, and 0 minor interactions.
6
Contraindicated
11
Major
0
Moderate
0
Minor
The combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, dizziness, extreme drowsiness, slowed or difficult breathing, and hypoxemia.
Mechanism
Tapentadol is an opioid analgesic with mu-opioid receptor agonist activity and norepinephrine reuptake inhibition. Clonazepam is a benzodiazepine that enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor. Concomitant use of these central nervous system (CNS) depressants leads to additive depressant effects, primarily on the respiratory and central nervous systems.
Clinical Management
Concomitant use of tapentadol and clonazepam is generally contraindicated due to the high risk of severe adverse outcomes, including death. If co-prescription is absolutely unavoidable, the lowest effective doses should be used for the shortest possible duration, and patients must be closely monitored for respiratory depression and sedation. Consider alternative treatments that do not involve co-prescribing opioids and benzodiazepines.
This combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, bradycardia, and hypotension. The FDA has issued a Black Box Warning highlighting these life-threatening risks.
Mechanism
Tapentadol is an opioid analgesic with mu-opioid receptor agonist activity and norepinephrine reuptake inhibition. Diazepam is a benzodiazepine that enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor. Concomitant use leads to synergistic central nervous system (CNS) depression by acting on different but complementary pathways.
Clinical Management
Concomitant use of tapentadol and diazepam is generally contraindicated due to the high risk of severe adverse outcomes. If co-prescription is absolutely unavoidable, use the lowest effective doses for the shortest possible duration, closely monitor for respiratory depression and sedation, and ensure naloxone is available. Consider alternative non-opioid or non-benzodiazepine treatments.
The concurrent use of tapentadol and temazepam significantly increases the risk of severe respiratory depression, profound sedation, hypotension, coma, and death. Patients may experience decreased level of consciousness, slowed or shallow breathing, and psychomotor impairment.
Mechanism
Tapentadol, an opioid analgesic, acts as a mu-opioid receptor agonist and norepinephrine reuptake inhibitor, producing central nervous system (CNS) depression. Temazepam, a benzodiazepine, enhances the effect of gamma-aminobutyric acid (GABA) at the GABA-A receptor, also leading to profound CNS depression. The co-administration results in an additive and synergistic depressant effect on the CNS.
Clinical Management
Due to the severe risks, concurrent use of tapentadol and temazepam is generally contraindicated. If co-prescription is absolutely unavoidable, use the lowest effective doses for the shortest possible duration, closely monitor patients for respiratory depression and sedation, and educate patients and caregivers on the signs of CNS depression. Consider alternative non-opioid or non-benzodiazepine treatments.
This combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, hypotension, and psychomotor impairment. Even with careful dose titration, the risk remains high.
Mechanism
Tapentadol, an opioid agonist, causes central nervous system (CNS) depression through mu-opioid receptor activation. Triazolam, a benzodiazepine, enhances the inhibitory effects of gamma-aminobutyric acid (GABA) at GABA-A receptors, also leading to CNS depression. The co-administration results in additive and synergistic CNS depressant effects.
Clinical Management
Concomitant use of opioids and benzodiazepines, including Tapentadol and Triazolam, is generally contraindicated due to the high risk of serious adverse outcomes. If no alternative treatment options are adequate, and the benefits outweigh the risks, prescribe the lowest effective doses for the shortest duration possible. Closely monitor patients for signs of respiratory depression and sedation, and educate them and their caregivers on these risks.
The concurrent use of tapentadol and midazolam significantly increases the risk of severe adverse outcomes including profound sedation, respiratory depression, coma, and death. Patients may exhibit decreased level of consciousness, hypoventilation, bradycardia, and hypotension.
Mechanism
Both tapentadol, an opioid analgesic, and midazolam, a benzodiazepine, are central nervous system (CNS) depressants. Their co-administration leads to an additive depressant effect on the CNS, primarily impacting the brainstem respiratory centers and leading to profound sedation and respiratory depression.
Clinical Management
Concomitant use of tapentadol and midazolam is contraindicated due to the high risk of respiratory depression and death. If co-administration is unavoidable, the lowest effective doses should be used for the shortest possible duration, and patients must be closely monitored for signs of respiratory depression and sedation. Naloxone should be readily available.
The concurrent use of tapentadol and chlordiazepoxide significantly increases the risk of profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, hypotension, and psychomotor impairment.
Mechanism
Tapentadol, an opioid analgesic with mu-opioid receptor agonism and norepinephrine reuptake inhibition, and chlordiazepoxide, a benzodiazepine that enhances GABAergic neurotransmission, both produce central nervous system (CNS) depression. Their co-administration results in synergistic depressant effects on the CNS, particularly on brainstem respiratory centers.
Clinical Management
Due to the severe risks, concomitant use of tapentadol and chlordiazepoxide is generally contraindicated. If no suitable alternative treatment options are available, and the benefits outweigh the risks, prescribe the lowest effective doses for the shortest duration possible, and monitor patients closely for signs of respiratory depression and sedation. Advise patients and caregivers about the risks and symptoms of CNS depression.
Patients may experience profound sedation, dizziness, confusion, and psychomotor impairment. There is an increased risk of respiratory depression, hypotension, and potentially life-threatening overdose symptoms. Impaired motor function can also increase the risk of falls and accidents.
Mechanism
Tapentadol is an opioid analgesic that acts as a mu-opioid receptor agonist and a norepinephrine reuptake inhibitor, leading to central nervous system (CNS) depression. Cyclobenzaprine is a centrally acting skeletal muscle relaxant structurally related to tricyclic antidepressants, which also causes significant CNS depression. The co-administration of these agents results in an additive depressant effect on the CNS.
Clinical Management
Concomitant use of tapentadol and cyclobenzaprine should generally be avoided due to the high risk of additive CNS depression. If co-administration is unavoidable, initiate both medications at the lowest effective doses and monitor patients closely for signs of sedation, respiratory depression, and cognitive impairment. Consider alternative non-opioid analgesics or non-pharmacological therapies for pain, and alternative muscle relaxants with less CNS depressant effects if appropriate.
Patients may experience profound sedation, respiratory depression, hypotension, and impaired psychomotor function. This can lead to increased risk of falls, accidental injury, and potentially life-threatening respiratory compromise. Dizziness, confusion, and decreased level of consciousness are also common.
Mechanism
Tapentadol is an opioid analgesic with mu-opioid receptor agonist activity and norepinephrine reuptake inhibition. Methocarbamol is a central nervous system (CNS) depressant that acts as a muscle relaxant, though its precise mechanism is not fully understood. Concomitant use results in an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of tapentadol and methocarbamol if possible. If co-administration is necessary, initiate both medications at the lowest effective doses and monitor patients closely for signs of CNS depression, especially during initiation or dose escalation. Educate patients about the risks and advise against driving or operating heavy machinery.
Patients may experience profound sedation, respiratory depression, hypotension, and psychomotor impairment, increasing the risk of falls and accidental injury. The combination can also lead to coma and death, particularly with higher doses or in vulnerable populations.
Mechanism
Tapentadol is a centrally acting analgesic with opioid agonist activity and norepinephrine reuptake inhibition. Carisoprodol is a centrally acting muscle relaxant that is metabolized to meprobamate, a Schedule IV controlled substance with anxiolytic and sedative properties. The co-administration of these agents leads to additive central nervous system (CNS) depression by enhancing GABAergic activity and opioid receptor agonism, respectively.
Clinical Management
Avoid concomitant use of tapentadol and carisoprodol due to the high risk of severe additive CNS depression. If co-administration is unavoidable, reduce the dosage of one or both drugs, closely monitor for signs of respiratory depression and sedation, and educate the patient on the risks. Consider alternative non-opioid analgesics or non-benzodiazepine muscle relaxants.
Patients may experience profound sedation, respiratory depression, hypotension, and impaired psychomotor function. This can lead to increased risk of falls, accidental injury, and potentially life-threatening respiratory compromise. Other effects include dizziness, confusion, and decreased level of consciousness.
Mechanism
Tapentadol is an opioid analgesic with mu-opioid receptor agonist activity and norepinephrine reuptake inhibition, both contributing to central nervous system (CNS) effects. Baclofen is a gamma-aminobutyric acid (GABA) analogue that acts as a GABA-B receptor agonist, primarily causing CNS depression and skeletal muscle relaxation. The co-administration of these agents results in additive CNS depressant effects.
Clinical Management
Concomitant use should generally be avoided due to the high risk of additive CNS and respiratory depression. If co-administration is unavoidable, initiate both medications at the lowest effective doses and titrate cautiously while closely monitoring for signs of respiratory depression and excessive sedation. Educate patients and caregivers about the risks and symptoms of CNS depression and advise against operating heavy machinery or driving.
Patients may experience profound sedation, dizziness, confusion, respiratory depression, hypotension, and psychomotor impairment. This can significantly increase the risk of falls, accidental injury, and life-threatening respiratory compromise.
Mechanism
Both tapentadol, an opioid analgesic, and tizanidine, a centrally acting alpha-2 adrenergic agonist muscle relaxant, cause central nervous system (CNS) depression. The co-administration of these agents results in an additive depressant effect on the CNS, leading to enhanced sedation and respiratory depression.
Clinical Management
Avoid concomitant use of tapentadol and tizanidine due to the high risk of additive CNS and respiratory depression. If co-administration is unavoidable, reduce the dosage of one or both drugs, monitor patients closely for signs of CNS depression and respiratory compromise, and educate them on the risks.
Patients may experience profound sedation, dizziness, confusion, and impaired psychomotor function. There is an increased risk of respiratory depression, which can be life-threatening, and hypotension. These effects significantly increase the risk of falls and accidental injury.
Mechanism
Tapentadol is an opioid analgesic with mu-opioid receptor agonist and norepinephrine reuptake inhibition properties, both contributing to central nervous system (CNS) depression. Metaxalone is a centrally acting skeletal muscle relaxant whose exact mechanism is not fully understood but is believed to involve general CNS depression. The coadministration of these agents leads to an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of tapentadol and metaxalone if possible. If coadministration is necessary, initiate both medications at the lowest effective doses and titrate slowly while closely monitoring for signs of CNS and respiratory depression. Educate the patient about the risks, advise against operating heavy machinery or driving, and instruct them to seek immediate medical attention for severe drowsiness or difficulty breathing.
Patients may experience increased sedation, dizziness, confusion, and psychomotor impairment. There is an elevated risk of respiratory depression, which can be life-threatening, and profound hypotension.
Mechanism
Tapentadol is an opioid analgesic with mu-opioid receptor agonist and norepinephrine reuptake inhibition properties, leading to central nervous system (CNS) depression. Chlorzoxazone is a centrally acting muscle relaxant that also causes CNS depression. The concomitant use of these agents results in additive CNS depressant effects.
Clinical Management
Concomitant use should generally be avoided. If co-administration is necessary, initiate both drugs at the lowest effective doses and titrate carefully while closely monitoring for signs of CNS depression, respiratory depression, and hypotension. Advise patients to avoid driving or operating heavy machinery and to avoid other CNS depressants, including alcohol.
Patients may experience severe respiratory depression, profound sedation, coma, and even death. Other clinical effects include dizziness, impaired psychomotor function, confusion, and hypotension, which significantly increase the risk of falls and accidental injury.
Mechanism
Tapentadol is an opioid analgesic with mu-opioid receptor agonist and norepinephrine reuptake inhibition properties, leading to central nervous system (CNS) depression. Orphenadrine is an anticholinergic and antihistaminic agent with muscle relaxant properties, which also contributes to CNS depression. The concomitant use of these agents results in an additive depressant effect on the CNS.
Clinical Management
Concomitant use should generally be avoided due to the high risk of severe adverse effects. If co-administration is unavoidable, reduce the dosage of one or both drugs, monitor patients closely for signs of respiratory depression and sedation, and limit the duration of therapy. Educate patients and caregivers on the risks and symptoms of CNS depression.
Concomitant use significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may exhibit decreased level of consciousness, bradycardia, hypotension, and hypoxemia. This interaction can also impair psychomotor function, increasing the risk of falls and accidents.
Mechanism
Both tapentadol (an opioid analgesic with norepinephrine reuptake inhibition) and lorazepam (a benzodiazepine) are central nervous system (CNS) depressants. Tapentadol's opioid activity primarily agonizes mu-opioid receptors, while lorazepam enhances the effect of the inhibitory neurotransmitter GABA at GABA-A receptors. The additive CNS depressant effects of these two drug classes lead to profound respiratory depression, sedation, and hypotension.
Clinical Management
Avoid concomitant use of tapentadol and lorazepam whenever possible due to the high risk of severe adverse outcomes, as highlighted by an FDA Black Box Warning. If co-prescription is absolutely necessary, use the lowest effective doses for the shortest possible duration, and closely monitor patients for signs of respiratory depression, sedation, and hypotension. Educate patients and caregivers about the risks and symptoms, and consider prescribing naloxone if appropriate.
The combination can lead to profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, slowed or shallow breathing, hypoxia, and hypotension. These effects can be rapid in onset and life-threatening.
Mechanism
Tapentadol, an opioid analgesic, acts as a mu-opioid receptor agonist and norepinephrine reuptake inhibitor, causing central nervous system (CNS) depression. Alprazolam, a benzodiazepine, enhances the effect of the inhibitory neurotransmitter GABA at GABA-A receptors, leading to further CNS depression. The synergistic CNS depressant effects of both drugs significantly increase the risk of adverse outcomes.
Clinical Management
Avoid concomitant use of opioids and benzodiazepines whenever possible. If co-prescription is unavoidable, use the lowest effective doses and shortest possible duration. Closely monitor patients for signs of respiratory depression and sedation, and educate them and their caregivers on these risks. Consider prescribing naloxone for at-risk patients.
Patients may experience severe sedation, respiratory depression (ranging from hypoventilation to respiratory arrest), profound hypotension, coma, and death. Other symptoms include dizziness, confusion, psychomotor impairment, and unresponsiveness.
Mechanism
Both tapentadol (an opioid analgesic) and oxazepam (a benzodiazepine) are central nervous system (CNS) depressants. Their co-administration leads to an additive depressant effect on the CNS, primarily by enhancing GABAergic neurotransmission (benzodiazepines) and activating mu-opioid receptors (tapentadol), leading to profound respiratory and CNS depression.
Clinical Management
Avoid concomitant use of tapentadol and oxazepam due to the high risk of severe adverse outcomes. If co-administration is unavoidable, prescribe the lowest effective doses for the shortest possible duration, and monitor patients closely for respiratory depression and sedation. Educate patients and caregivers on the risks and symptoms of CNS depression.
For complete prescribing information:
View full TAPENTADOL HYDROCHLORIDE monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.